News & Updates

Seladelpar improves markers of cholestasis, reduces pruritus in patients with PBC

01 Dec 2023 by

Treatment with seladelpar significantly improves serum markers of cholestasis, including alkaline phosphatase (ALP) and total bilirubin (TB), and reduces pruritus in patients with primary biliary cholangitis (PBC) who are at risk for disease progression, according to the RESPONSE trial presented at The Liver Meeting 2023.

Seladelpar improves markers of cholestasis, reduces pruritus in patients with PBC

01 Dec 2023

Hepatocellular carcinoma risk diminishes with time following HCV eradication

30 Nov 2023

Among individuals with cirrhosis and cured hepatitis C virus (HCV) infection, the risk of hepatocellular carcinoma tapers off progressively through 6 years after HCV eradication, as shown in a study. However, the risk remains above thresholds that require screening.

Hepatocellular carcinoma risk diminishes with time following HCV eradication

30 Nov 2023

Elafibranor for primary biliary cholangitis scores high in phase III trial

29 Nov 2023 by

The oral, dual peroxisome proliferator-activated receptor-α/δ agonist elafibranor improves biomarkers of cholestasis and quells itching in patients with primary biliary cholangitis, while having an acceptable safety profile, as shown in the phase III ELATIVE study.

Elafibranor for primary biliary cholangitis scores high in phase III trial

29 Nov 2023

Givosiran delivers safe, sustained improvements in acute hepatic porphyria

28 Nov 2023 by

Long-term monthly treatment with givosiran has good tolerability and offers continuous improvements to patients with acute hepatic porphyria (AHP), results of the phase III ENVISION trial have shown.

Givosiran delivers safe, sustained improvements in acute hepatic porphyria

28 Nov 2023

Palliative care in cancer: Which central venous access devices are associated with higher complication rates?

27 Nov 2023 by

A systematic review and meta-analysis by researchers from the University of Hong Kong has shown that the use of peripherally inserted central catheters (PICCs) is associated with a higher rate of complications than central lines in terminally ill cancer patients with central venous access devices (CVADs) for palliative care. No conclusions were reached regarding the use of totally implanted ports (PORTs), as no studies on PORTs were eligible for analysis.

Palliative care in cancer: Which central venous access devices are associated with higher complication rates?

27 Nov 2023

Novel tri-agonist confers significant gains for MASLD patients

24 Nov 2023 by

In a substudy of a phase II obesity trial, individuals with MASLD* and obesity benefited significantly from retatrutide, a once-weekly, injectable, novel synthetic molecule that has shown potent agonist action at GIP**, GLP-1***, and glucagon receptors.

Novel tri-agonist confers significant gains for MASLD patients

24 Nov 2023

Cholecystectomy during pregnancy supported in large study

24 Nov 2023

For expectant mothers with acute cholecystitis (AC), undergoing cholecystectomy lowers the risk of adverse pregnancy outcomes, according to a large study.

Cholecystectomy during pregnancy supported in large study

24 Nov 2023

Remnant cholesterol predicts NAFLD development

23 Nov 2023

Serum levels of remnant cholesterol may be used to assess an individual’s susceptibility to developing nonalcoholic fatty liver disease (NAFLD), independent of traditional lipid profiles, suggests a recent study.

Remnant cholesterol predicts NAFLD development

23 Nov 2023

HBV vaccine improves survival of patients with chronic liver disease

22 Nov 2023 by

Vaccination against hepatitis B virus (HBV) results in meaningful improvements in survival among patients with different kinds of chronic liver diseases, suggests a study presented at AASLD 2023.

HBV vaccine improves survival of patients with chronic liver disease

22 Nov 2023

Can elexacaftor/tezacaftor/ivacaftor cause liver damage in adults with cystic fibrosis?

21 Nov 2023 by

Treatment with elexacaftor/tezacaftor/ivacaftor (ETI) rarely results in severe drug-induced liver injury among adults with cystic fibrosis, as shown in a study presented at AASLD 2023. Moreover, serum markers of fibrosis have increased but remain within normal range.

Can elexacaftor/tezacaftor/ivacaftor cause liver damage in adults with cystic fibrosis?

21 Nov 2023

News & Updates

Filter by Specialty:

Specialty:

Seladelpar improves markers of cholestasis, reduces pruritus in patients with PBC

Seladelpar improves markers of cholestasis, reduces pruritus in patients with PBC

Hepatocellular carcinoma risk diminishes with time following HCV eradication

Hepatocellular carcinoma risk diminishes with time following HCV eradication

Elafibranor for primary biliary cholangitis scores high in phase III trial

Elafibranor for primary biliary cholangitis scores high in phase III trial

Givosiran delivers safe, sustained improvements in acute hepatic porphyria

Givosiran delivers safe, sustained improvements in acute hepatic porphyria

Palliative care in cancer: Which central venous access devices are associated with higher complication rates?

Palliative care in cancer: Which central venous access devices are associated with higher complication rates?

Novel tri-agonist confers significant gains for MASLD patients

Novel tri-agonist confers significant gains for MASLD patients

Cholecystectomy during pregnancy supported in large study

Cholecystectomy during pregnancy supported in large study

Remnant cholesterol predicts NAFLD development

Remnant cholesterol predicts NAFLD development

HBV vaccine improves survival of patients with chronic liver disease

HBV vaccine improves survival of patients with chronic liver disease

Can elexacaftor/tezacaftor/ivacaftor cause liver damage in adults with cystic fibrosis?

Can elexacaftor/tezacaftor/ivacaftor cause liver damage in adults with cystic fibrosis?